MedTrace Logo

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

NCT02791230 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1733

Last updated 2025-02-03

Study results available
· View outcomes & findings →

Summary

Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy

Conditions

  • Transthyretin (TTR) Amyloid Cardiomyopathy

Interventions

DRUG

Tafamidis

Soft gel capsules administered once a day for 60 months

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-13
Primary Completion
2023-10-26
Completion
2023-11-02
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Canada
  • Czechia
  • France
  • Germany
  • Hong Kong
  • Italy
  • Japan
  • Netherlands
  • Spain
  • Sweden
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02791230 on ClinicalTrials.gov